Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

The two-year results of TRILUMINATE trial showed the first objective benefit to use of Abbott Laboratories’ Triclip ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) on March 28 and set a price target of DKK750.00. The ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...